View in EDS HTML Full Text PDF Full Text

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.

Saved in:
Bibliographic Details
Title: NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Authors: Lee EQ; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Zhang P; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania., Wen PY; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Gerstner ER; Massachusetts General Hospital, Boston, Massachusetts., Reardon DA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts., Aldape KD; Toronto General Hospital, Toronto, Ontario, Canada., deGroot JF; The University of Texas MD Anderson Cancer Center, Houston, Texas., Pan E; University of Texas Southwestern Medical Center, Dallas, Texas., Raizer JJ; Northwestern University, Evanston, Illinois., Kim LJ; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Chmura SJ; University of Chicago Comprehensive Cancer Center, Chicago, Illinois., Robins HI; University of Wisconsin Hospital and Clinics, Madison, Wisconsin., Connelly JM; Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin., Battiste JD; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma., Villano JL; University of Kentucky, Lexington, Kentucky., Wagle N; University of Southern California, Los Angeles, California., Merrell RT; North Shore University Health System, Evanston, Illinois., Wendland MM; The US Oncology Network-Willamette Valley Cancer Institute, Eugene, Oregon., Mehta MP; Baptist Hospital of Miami, Miami, Florida.
Source: Cancer [Cancer] 2020 Jun 15; Vol. 126 (12), pp. 2821-2828. Date of Electronic Publication: 2020 Mar 10.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32154928
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lee+EQ%22">Lee EQ</searchLink>; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Zhang+P%22">Zhang P</searchLink>; NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Wen+PY%22">Wen PY</searchLink>; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Gerstner+ER%22">Gerstner ER</searchLink>; Massachusetts General Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Reardon+DA%22">Reardon DA</searchLink>; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Aldape+KD%22">Aldape KD</searchLink>; Toronto General Hospital, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22deGroot+JF%22">deGroot JF</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Pan+E%22">Pan E</searchLink>; University of Texas Southwestern Medical Center, Dallas, Texas.<br /><searchLink fieldCode="AU" term="%22Raizer+JJ%22">Raizer JJ</searchLink>; Northwestern University, Evanston, Illinois.<br /><searchLink fieldCode="AU" term="%22Kim+LJ%22">Kim LJ</searchLink>; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Chmura+SJ%22">Chmura SJ</searchLink>; University of Chicago Comprehensive Cancer Center, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Robins+HI%22">Robins HI</searchLink>; University of Wisconsin Hospital and Clinics, Madison, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Connelly+JM%22">Connelly JM</searchLink>; Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin.<br /><searchLink fieldCode="AU" term="%22Battiste+JD%22">Battiste JD</searchLink>; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.<br /><searchLink fieldCode="AU" term="%22Villano+JL%22">Villano JL</searchLink>; University of Kentucky, Lexington, Kentucky.<br /><searchLink fieldCode="AU" term="%22Wagle+N%22">Wagle N</searchLink>; University of Southern California, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Merrell+RT%22">Merrell RT</searchLink>; North Shore University Health System, Evanston, Illinois.<br /><searchLink fieldCode="AU" term="%22Wendland+MM%22">Wendland MM</searchLink>; The US Oncology Network-Willamette Valley Cancer Institute, Eugene, Oregon.<br /><searchLink fieldCode="AU" term="%22Mehta+MP%22">Mehta MP</searchLink>; Baptist Hospital of Miami, Miami, Florida.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2020 Jun 15; Vol. 126 (12), pp. 2821-2828. <i>Date of Electronic Publication: </i>2020 Mar 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32154928
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.32811
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2821
    Titles:
      – TitleFull: NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lee EQ
      – PersonEntity:
          Name:
            NameFull: Zhang P
      – PersonEntity:
          Name:
            NameFull: Wen PY
      – PersonEntity:
          Name:
            NameFull: Gerstner ER
      – PersonEntity:
          Name:
            NameFull: Reardon DA
      – PersonEntity:
          Name:
            NameFull: Aldape KD
      – PersonEntity:
          Name:
            NameFull: deGroot JF
      – PersonEntity:
          Name:
            NameFull: Pan E
      – PersonEntity:
          Name:
            NameFull: Raizer JJ
      – PersonEntity:
          Name:
            NameFull: Kim LJ
      – PersonEntity:
          Name:
            NameFull: Chmura SJ
      – PersonEntity:
          Name:
            NameFull: Robins HI
      – PersonEntity:
          Name:
            NameFull: Connelly JM
      – PersonEntity:
          Name:
            NameFull: Battiste JD
      – PersonEntity:
          Name:
            NameFull: Villano JL
      – PersonEntity:
          Name:
            NameFull: Wagle N
      – PersonEntity:
          Name:
            NameFull: Merrell RT
      – PersonEntity:
          Name:
            NameFull: Wendland MM
      – PersonEntity:
          Name:
            NameFull: Mehta MP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 06
              Text: 2020 Jun 15
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 126
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1